{"id":"active","rwe":[{"pmid":"41879627","year":"2026","title":"Health and Medical Preparedness and Response to the 2024 Republican National Convention.","journal":"Prehospital emergency care"},{"pmid":"41879559","year":"2026","title":"Association Between Physical Activity and Cognitive Function: Observational and Genetic Analysis.","journal":"Journal of gerontological nursing"},{"pmid":"41879521","year":"2026","title":"The impact of dynamic hyperedge activation mechanism on the evolution of cooperation on hypergraphs.","journal":"Chaos (Woodbury, N.Y.)"},{"pmid":"41879439","year":"2026","title":"Ocrelizumab Discontinuation vs. Continuation After Safety Events: Comparative Insights from MSBase.","journal":"Current neuropharmacology"},{"pmid":"41879156","year":"2026","title":"Wearable devices and cardiovascular health: revolutionizing remote monitoring and disease prevention.","journal":"European heart journal"}],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"Reported 197 times in FAERS database"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"Reported 166 times in FAERS database"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"Reported 150 times in FAERS database"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"Reported 135 times in FAERS database"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"Reported 130 times in FAERS database"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"Reported 128 times in FAERS database"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"Reported 113 times in FAERS database"},{"date":"","signal":"PRODUCT DOSE OMISSION ISSUE","source":"FDA FAERS","actionTaken":"Reported 111 times in FAERS database"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"Reported 101 times in FAERS database"},{"date":"","signal":"FALL","source":"FDA FAERS","actionTaken":"Reported 90 times in FAERS database"},{"date":"20150429","signal":"Recall: Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.","source":"FDA Enforcement","actionTaken":"Classification: Class II. Status: Terminated"},{"date":"20150429","signal":"Recall: Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.","source":"FDA Enforcement","actionTaken":"Classification: Class II. Status: Terminated"},{"date":"20150429","signal":"Recall: Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.","source":"FDA Enforcement","actionTaken":"Classification: Class II. Status: Terminated"},{"date":"20150429","signal":"Recall: Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.","source":"FDA Enforcement","actionTaken":"Classification: Class II. Status: Terminated"},{"date":"20150429","signal":"Recall: Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.","source":"FDA Enforcement","actionTaken":"Classification: Class II. Status: Terminated"}],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT04919122","NCT00728468","NCT05780541","NCT00563524","NCT05407805","NCT03424005","NCT03351751","NCT03794154","NCT05509894","NCT05696795","NCT00195507","NCT00562354","NCT00092001","NCT01965600","NCT00761631","NCT00263328","NCT02262767","NCT00617760","NCT05661760","NCT04395950","NCT02288247","NCT01546038","NCT00920478","NCT00366340","NCT00937508"],"_pubmed":{"count":1310986,"papers":[{"date":"2026 Mar 27","pmid":"41891211","title":"Orbital-Selective Modulation of Spatial p(z)-s Hybridization for Enhanced Photocatalytic H(2) Evolution: Insights From NiSe@ReS(2+) (x) Cocatalyst.","authors":"Gao D","journal":"Angewandte Chemie (International ed. in English)"},{"date":"2026 Apr","pmid":"41891207","title":"Family Members' Experiences of Weaning From Mechanical Ventilation in Intensive Care: A Hermeneutic Phenomenological Study.","authors":"Tingsvik C","journal":"Nursing open"},{"date":"2026 Mar 27","pmid":"41891157","title":"Association Between Healthy Lifestyle Behaviors and Mental Health Symptoms in Children With Autism and ADHD: A Latent Profile Analysis.","authors":"Bourke M","journal":"Autism research : official journal of the International Society for Autism Research"},{"date":"2026 Mar 27","pmid":"41891141","title":"Divergent Thioamide Synthesis via Umpolung C-N Bond Formation from Nitroethane in Aqueous Medium.","authors":"Bhatt PR","journal":"The Journal of organic chemistry"},{"date":"2026","pmid":"41891070","title":"#TransTok: A digital ethnographic study using content analysis to investigate transgender and gender diverse 'for you page' content on TikTok that may affect mental health.","authors":"Paciente R","journal":"International journal of transgender health"}]},"_rxnorm":{"forms":[]},"aliases":[],"patents":[],"pricing":[],"_recalls":[{"date":"20150429","reason":"Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.","status":"Terminated","classification":"Class II"},{"date":"20150429","reason":"Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.","status":"Terminated","classification":"Class II"},{"date":"20150429","reason":"Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.","status":"Terminated","classification":"Class II"},{"date":"20150429","reason":"Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.","status":"Terminated","classification":"Class II"},{"date":"20150429","reason":"Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.","status":"Terminated","classification":"Class II"}],"offLabel":[],"timeline":[{"date":"","type":"positive","milestone":"EMA marketing authorisation — Active","regulator":"EMA","description":"Holder: . Area: "},{"date":"","type":"positive","milestone":"MHRA licence — PL 12345/0001","regulator":"MHRA","description":"Licensed in the United Kingdom"},{"date":"2007","type":"neutral","milestone":"Phase 2 Initiated","regulator":"FDA","description":"Phase 2 trial (Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer) — Carcinoma, Non-Small-Cell Lung"},{"date":"2007","type":"neutral","milestone":"Phase 3 Initiated","regulator":"FDA","description":"Phase 3 trial (Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Adults Aged >= 50 Year) — Healthy"},{"date":"2010","type":"neutral","milestone":"Phase 1 Initiated","regulator":"FDA","description":"Phase 1 trial (Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis) — Psoriasis"},{"date":"2010","type":"neutral","milestone":"Phase 4 Initiated","regulator":"FDA","description":"Phase 4 trial (Smoking Cessation Program in the Preadmission Clinic) — Smoking"}],"_dailymed":{"setId":"4b1cdab1-3e50-4ec3-e063-6394a90af75e","title":"RICHTOFIT RAPID ACTIVE ARTHRITIS (MENTHOL AND CAMPHOR) GEL [RICHTOFIT LIMITED LIABILITY COMPANY]","labeler":"","products":[],"publishedDate":"Mar 18, 2026"},"_drugbank":{"source":"DrugBank","halfLife":"","metabolism":"","proteinBinding":"","bioavailability":""},"aiSummary":"Active is a sunscreen agent that works by blocking ultraviolet radiation to prevent sunburn and reduce skin cancer risk. As a topical photoprotective agent, it provides broad-spectrum UV protection when used as directed alongside other sun protection measures, making it a foundational component of comprehensive sun safety strategies.","brandName":"Active","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"","drugClass":"Sisunatovir","explanation":"Active is a sunscreen that acts as a barrier between your skin and the sun's ultraviolet (UV) rays. When applied to your skin, it either sits on the surface to reflect UV rays away or absorbs into the outer layers to convert those rays into harmless heat. Either way, the goal is the same: stop damaging UV radiation from penetrating deep into your skin where it can cause immediate sunburn and long-term damage.\n\nThe sun damage that leads to skin cancer and premature aging happens at the cellular level when UV rays penetrate your skin and damage the DNA in your cells. By blocking or absorbing these rays before they go deep, Active prevents this cellular damage from occurring in the first place. This is why consistent use is so important—every time you're exposed to the sun without protection, your cells accumulate more damage.\n\nFor Active to work effectively, you need to use it correctly and reapply it regularly, especially after swimming or sweating. It's also most effective when combined with other sun protection strategies like wearing protective clothing, seeking shade, and avoiding peak sun hours. Think of it as one important part of a complete sun safety plan rather than a standalone solution.","oneSentence":"Sisunatovir","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"active","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Respiratory Syncytial Virus Infections","phase":"discontinued","trialId":"","patients":null,"diseaseId":"infectious-disease","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07135232","phase":"NA","title":"The Effects of Resistance Training and a Plant-Based Supplement on Perimenopausal Symptoms and Muscle Health.","status":"RECRUITING","sponsor":"Leeds Beckett University","startDate":"2026-03-01","conditions":"Perimenopause, Menopause","enrollment":72,"completionDate":"2027-04-01","primaryEndpoint":"Depressive Symptom Score at week 4"},{"nctId":"NCT06097663","phase":"PHASE2","title":"A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-15","conditions":"Coronary Heart Disease, Clonal Hematopoiesis of Indeterminate Potential (CHIP)","enrollment":31,"completionDate":"2024-11-04","primaryEndpoint":"Ratio to Baseline Serum Levels of IL-6 for DFV890 Based on an Emax Model"},{"nctId":"NCT06868914","phase":"PHASE1","title":"Phase I Trial of High-Density Theta Burst Stimulation (hdTBS)","status":"NOT_YET_RECRUITING","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2026-04-01","conditions":"Healthy Volunteers","enrollment":35,"completionDate":"2028-01-13","primaryEndpoint":"Clinically significant adverse events as collected on the Noninvasive Brain Stimulation (NIBS) monitoring questionnaire and evaluated by the MAI in combination with the serious adverse event reports."},{"nctId":"NCT06635109","phase":"","title":"Investigating the Effect of Carpal Tunnel Syndrome on Activity and Participation","status":"COMPLETED","sponsor":"Kutahya Health Sciences University","startDate":"2024-11-15","conditions":"Carpal Tunnel Syndrome","enrollment":156,"completionDate":"2026-01-15","primaryEndpoint":"Short Form - 36 Quality of Life Questionnaire (SF-36)"},{"nctId":"NCT07042945","phase":"PHASE1","title":"MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-09","conditions":"HIV Infection","enrollment":28,"completionDate":"2026-06-22","primaryEndpoint":"Participants with averse events (AEs)"},{"nctId":"NCT03654105","phase":"PHASE2","title":"Screening and Multiple Intervention on Lung Epidemics","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2019-07-23","conditions":"Inflammation, Smoking Cessation, Diet Modification","enrollment":2000,"completionDate":"2026-12-31","primaryEndpoint":"Change in chronic inflammatory status"},{"nctId":"NCT07485959","phase":"NA","title":"The Effect of NP-2006 on Sleep Quality and Health","status":"COMPLETED","sponsor":"Hanpoong Nature Pharm Co., Ltd.","startDate":"2023-05-12","conditions":"Sleep Disorder (Disorder)","enrollment":48,"completionDate":"2025-08-13","primaryEndpoint":"Change from Baseline in Pittsburgh Sleep Quality Index (PSQI) Score"},{"nctId":"NCT07433556","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of IY-828026 in Healthy Volunteers","status":"RECRUITING","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2026-03-23","conditions":"Healhty","enrollment":86,"completionDate":"2027-06","primaryEndpoint":"Number of Participants With Adverse Events"},{"nctId":"NCT06857929","phase":"NA","title":"\"Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition\"","status":"RECRUITING","sponsor":"IMDEA Food","startDate":"2026-03-01","conditions":"Metabolic Syndrome, Obesity Prevention, Obesity and Overweight","enrollment":106,"completionDate":"2028-09-30","primaryEndpoint":"Percentage of weight loss"},{"nctId":"NCT00004577","phase":"","title":"Study of New Magnetic Resonance Imaging Methods of the Brain","status":"RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2000-07-01","conditions":"Healthy Volunteer, Magnetic Resonance Imaging, Healthy","enrollment":1100,"completionDate":"","primaryEndpoint":"The purpose of this study is to develop and evaluate new MR pulse sequences and hardware for performing anatomical and functional MRI in the CNS at, 3.0T, and 7T with a high spatial resolution."},{"nctId":"NCT03055013","phase":"PHASE3","title":"Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-28","conditions":"Metastatic Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v7","enrollment":819,"completionDate":"2031-06-09","primaryEndpoint":"Recurrence-free Survival (RFS) Rate at 5 Years"},{"nctId":"NCT07155174","phase":"PHASE2","title":"A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-11-25","conditions":"Small Cell Lung Cancer","enrollment":180,"completionDate":"2031-09","primaryEndpoint":"Number of Participants with Adverse Events (AE)s"},{"nctId":"NCT05768932","phase":"PHASE1","title":"BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"SillaJen, Inc.","startDate":"2022-12-14","conditions":"Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer","enrollment":260,"completionDate":"2026-12-24","primaryEndpoint":"Part 1: Number of Participants With Adverse Events as a Measure of Safety and Tolerability"},{"nctId":"NCT04569591","phase":"NA","title":"DDAVP for Pituitary Adenoma","status":"RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2026-03-09","conditions":"Cushing's Disease, Pituitary Adenoma","enrollment":22,"completionDate":"2028-02-26","primaryEndpoint":"The primary outcome measure will be defined as whether or not DDAVP-stimulated PET imaging demonstrates tumor in MRI-negative cases."},{"nctId":"NCT07494305","phase":"PHASE2","title":"Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.","status":"RECRUITING","sponsor":"LB Pharmaceuticals Inc.","startDate":"2026-01-23","conditions":"Bipolar I Disorder","enrollment":320,"completionDate":"2028-02","primaryEndpoint":"Change From Baseline in Montgomery Åsberg Depression Rating -10 core symptom scale (MADRS-10)"},{"nctId":"NCT06985056","phase":"NA","title":"Reducing Symptom Burden Through Physical Exercise in Melanoma Patients","status":"RECRUITING","sponsor":"Universität Duisburg-Essen","startDate":"2025-08-18","conditions":"Malignant Melanoma","enrollment":104,"completionDate":"2027-11","primaryEndpoint":"Fatigue"},{"nctId":"NCT06118515","phase":"PHASE1","title":"A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-02-19","conditions":"Congenital Cytomegalovirus Infection","enrollment":12,"completionDate":"2026-08-31","primaryEndpoint":"Plasma letermovir area under the curve (AUC24) concentrations"},{"nctId":"NCT07396584","phase":"PHASE1, PHASE2","title":"HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor","status":"RECRUITING","sponsor":"Hutchmed","startDate":"2026-03-04","conditions":"Solid Tumors, Adult","enrollment":186,"completionDate":"2029-01-30","primaryEndpoint":"Maximum Tolerated Dose (MTD) and/or recommended dose(s) for expansion(RDE)"},{"nctId":"NCT06498635","phase":"PHASE3","title":"Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-04-01","conditions":"Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":306,"completionDate":"2039-07-15","primaryEndpoint":"Disease-free survival (DFS)"},{"nctId":"NCT07494539","phase":"NA","title":"Induction of Labor by Cervical Ripening and Transcutaneous Electrical Nerve Stimulation (TENS)","status":"NOT_YET_RECRUITING","sponsor":"HOT Noémie","startDate":"2026-04-01","conditions":"Labor Pain, Induction of Labor","enrollment":132,"completionDate":"2028-04-01","primaryEndpoint":"Cervical dilation at analgesia initiation or delivery without epidural analgesia"},{"nctId":"NCT03559283","phase":"NA","title":"fNIRS in the Evaluation of Cognitive-motor Interference in Post-stroke Patients","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2018-11-26","conditions":"D020521","enrollment":11,"completionDate":"2019-06-26","primaryEndpoint":"Cost of the Double Task"},{"nctId":"NCT06450444","phase":"NA","title":"The RECLAIM Study.","status":"RECRUITING","sponsor":"Salvia BioElectronics","startDate":"2024-06-24","conditions":"Chronic Migraine, High Frequency Episodic Migraine","enrollment":110,"completionDate":"2029-01-31","primaryEndpoint":"Safety Evaluation"},{"nctId":"NCT07497971","phase":"NA","title":"Utilizing Electronic Modules to Educate on Sexual Health Practices During Pregnancy","status":"NOT_YET_RECRUITING","sponsor":"Loyola University","startDate":"2026-03","conditions":"Sexual Health Education During Pregnancy, Communication About Sexual Health in Prenatal Care, Sexual Function and Intimacy in Pregnancy","enrollment":100,"completionDate":"2027-02","primaryEndpoint":"Change in Sexual Health Knowledge During Pregnancy"},{"nctId":"NCT05241041","phase":"NA","title":"Effects of Positive Psychological Group Psychotherapy and Auricular Acupressure on Withdrawal Symptoms","status":"COMPLETED","sponsor":"Inha University Hospital","startDate":"2021-09-13","conditions":"Gambling","enrollment":198,"completionDate":"2025-09-28","primaryEndpoint":"Change from Problem Gambling Severity during 1 year"},{"nctId":"NCT04512456","phase":"NA","title":"Cardiovascular Responses to Exercise in People Living With HIV/AIDS: Effects of Exercise Training","status":"RECRUITING","sponsor":"Instituto Nacional de Cardiologia de Laranjeiras","startDate":"2024-08-01","conditions":"HIV Infections","enrollment":63,"completionDate":"2026-12-31","primaryEndpoint":"Change from Baseline Blood Pressure at 3 months"},{"nctId":"NCT01212003","phase":"","title":"Training Protocol on the Natural History of Tuberculosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-06-30","conditions":"Mycobacterium Infections, Tuberculosis, Multidrug-Resistant, Latent Tuberculosis","enrollment":150,"completionDate":"","primaryEndpoint":"Increase in the number of TB patients being actively followed at the NIH CC to provide information on TB patients with DS and drug-resistant disease for hypothesis generation and hands-on experience i"},{"nctId":"NCT07105943","phase":"NA","title":"Manipulating Exercise Intensity and Affective Responses for Cardiac Rehabilitation Program Acute Coronary Syndrome Patients","status":"NOT_YET_RECRUITING","sponsor":"Instituto Politécnico de Leiria","startDate":"2026-03-01","conditions":"Affect and Exertion During and Post-exercise","enrollment":52,"completionDate":"2028-03-31","primaryEndpoint":"Physical activity levels by International Physical Activity Questionnaire - Short Form"},{"nctId":"NCT04943224","phase":"PHASE2","title":"Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients","status":"RECRUITING","sponsor":"Anna Raciborska","startDate":"2021-04-01","conditions":"Histiocytosis","enrollment":12,"completionDate":"2027-06-30","primaryEndpoint":"Event-free survival (EFS)"},{"nctId":"NCT04933474","phase":"NA","title":"Pragmatic Comparative Effectiveness Trial of Evidence-based, On-demand, Digital Behavioral Treatments for Chronic Pain","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2022-03-23","conditions":"Chronic Pain","enrollment":330,"completionDate":"2024-06-12","primaryEndpoint":"Change From Baseline to Week 8 in Daily Pain Intensity"},{"nctId":"NCT07024784","phase":"PHASE2","title":"A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-07-30","conditions":"Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer","enrollment":377,"completionDate":"2028-02","primaryEndpoint":"Number of Participants With Dose-limiting Toxicities (DLTs)"},{"nctId":"NCT07170033","phase":"NA","title":"The Effect of the DASH Diet on Treatment Outcomes in Adults Diagnosed With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Istanbul Health and Technology University","startDate":"2024-05-06","conditions":"Rheumatoid Arthritis","enrollment":49,"completionDate":"2025-10-06","primaryEndpoint":"Change in Disease Activity Score-28 (DAS-28)"},{"nctId":"NCT05139017","phase":"PHASE2, PHASE3","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-14","conditions":"DLBCL, Diffuse Large B-Cell Lymphoma","enrollment":290,"completionDate":"2027-09-24","primaryEndpoint":"Number of participants who experienced dose-limiting toxicities (DLTs) in Part 1"},{"nctId":"NCT03811015","phase":"PHASE3","title":"Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-16","conditions":"Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":636,"completionDate":"2027-01-01","primaryEndpoint":"Overall survival (OS)"},{"nctId":"NCT06972446","phase":"PHASE2","title":"A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-06-20","conditions":"Rheumatoid Arthritis","enrollment":180,"completionDate":"2027-11","primaryEndpoint":"Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response"},{"nctId":"NCT06996990","phase":"","title":"Injury Risk Factors in Volleyball Players","status":"NOT_YET_RECRUITING","sponsor":"Izmir Democracy University","startDate":"2026-04-15","conditions":"Injury;Sports, Athletic Injuries","enrollment":28,"completionDate":"2027-06-30","primaryEndpoint":"Injury risc assessment"},{"nctId":"NCT07497113","phase":"NA","title":"The Effects of Commercially Available High Protein Drink on Amino Acid Bioavailability and Recovery From Muscle Fatiguing Exercise in 18-45-year-old Male and Female Participants.","status":"COMPLETED","sponsor":"Anglia Ruskin University","startDate":"2025-03-01","conditions":"Healthy Participants","enrollment":62,"completionDate":"2026-02-28","primaryEndpoint":"Essential Amino Acids"},{"nctId":"NCT07496060","phase":"PHASE4","title":"Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas","status":"COMPLETED","sponsor":"Fayoum University","startDate":"2025-08-10","conditions":"Anterior Chamber Granulomatous Uveitis","enrollment":66,"completionDate":"2026-01-13","primaryEndpoint":"resolution of the anterior chamber inflammation and granulomas."},{"nctId":"NCT06456346","phase":"PHASE3","title":"Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-16","conditions":"Essential Thrombocythemia","enrollment":300,"completionDate":"2028-03-24","primaryEndpoint":"Durable Clinicohematologic Response (DCHR) Rate"},{"nctId":"NCT07497269","phase":"NA","title":"Conventional vs Pulsed RF in Coccydynia","status":"NOT_YET_RECRUITING","sponsor":"Adana City Training and Research Hospital","startDate":"2026-04-01","conditions":"Back Pain","enrollment":90,"completionDate":"2028-04-01","primaryEndpoint":"The Numeric Rating Scale (NRS)"},{"nctId":"NCT06154252","phase":"PHASE2, PHASE3","title":"RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy","status":"RECRUITING","sponsor":"Cabaletta Bio","startDate":"2023-12-20","conditions":"Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome","enrollment":74,"completionDate":"2028-07","primaryEndpoint":"Phase 1/2: Incidence and severity of adverse events (AEs)"},{"nctId":"NCT07497425","phase":"NA","title":"Neuroimmune Responses to Exercise in Chronic Back Pain","status":"RECRUITING","sponsor":"McGill University","startDate":"2025-06-01","conditions":"Chronic Low Back Pain (CLBP)","enrollment":216,"completionDate":"2029-06-30","primaryEndpoint":"Chronic Low Back Pain Intensity"},{"nctId":"NCT06459180","phase":"PHASE3","title":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-24","conditions":"Cervical Cancer","enrollment":686,"completionDate":"2028-06-15","primaryEndpoint":"Objective Response Rate (ORR) in Sacituzumab Tirumotecan Run-in"},{"nctId":"NCT06982222","phase":"PHASE1","title":"Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-31","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma","enrollment":24,"completionDate":"2027-02-12","primaryEndpoint":"Frequency of dose-limiting toxicities"},{"nctId":"NCT06023537","phase":"NA","title":"Using Technology to Investigate Lapses in a Weight Loss Program Among Individuals With Overweight and Obesity","status":"COMPLETED","sponsor":"Williams College","startDate":"2023-07-11","conditions":"Obesity, Weight Loss","enrollment":119,"completionDate":"2025-08-05","primaryEndpoint":"Physical activity lapse/intention-behavior gap"},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75,"completionDate":"2026-10-01","primaryEndpoint":"Describe natural history"},{"nctId":"NCT02911103","phase":"PHASE1, PHASE2","title":"Deep Brain Stimulation Surgery for Focal Hand Dystonia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2018-01-17","conditions":"Dystonia, Focal Dystonia, Musician's Dystonia","enrollment":5,"completionDate":"2029-02-02","primaryEndpoint":"To confirm the safety of VOA/VOP thalamic DBS in FHD"},{"nctId":"NCT01927783","phase":"","title":"Heart Health Study in Washington D.C. to Develop a Community-Based Behavioral Weight Loss Intervention","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2014-02-08","conditions":"Cardiovascular Disease, Obesity","enrollment":200,"completionDate":"","primaryEndpoint":"estimate CVD risk factors in Ward 5,7,8"},{"nctId":"NCT04050410","phase":"EARLY_PHASE1","title":"Autonomic Determinants of POTS - Pilot1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2019-08-27","conditions":"Postural Tachycardia Syndrome","enrollment":48,"completionDate":"2026-12-31","primaryEndpoint":"Change in Orthostatic Symptom Burden [delta (delta VOSS)]"},{"nctId":"NCT07116109","phase":"NA","title":"Neuromodulation + Prolonged Exposure Therapy: Evaluation of a Technology-Enhanced, Integrated Treatment for Pain and PTSD","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2025-07-01","conditions":"Chronic Pain, Post Traumatic Stress Disorder (PTSD)","enrollment":146,"completionDate":"2029-06-30","primaryEndpoint":"Change in pain intensity as measured by the Defense and Veterans Pain Rating Scale (DVPRS)"},{"nctId":"NCT07489404","phase":"NA","title":"Plyometric Training on Sand vs Firm Ground in Young Adults","status":"COMPLETED","sponsor":"University of Manouba","startDate":"2024-09-01","conditions":"Lower Limb Injuries","enrollment":57,"completionDate":"2024-12-01","primaryEndpoint":"Change in Squat Jump (SJ) height (cm)"},{"nctId":"NCT06949969","phase":"NA","title":"Alesis OSA-1 Obstructive Sleep Apnea Treatment","status":"COMPLETED","sponsor":"Photonica USA, LLC","startDate":"2025-05-01","conditions":"Obstructive Sleep Apnea","enrollment":35,"completionDate":"2025-11-30","primaryEndpoint":"AHI Events"},{"nctId":"NCT07495254","phase":"NA","title":"Effectiveness of Combined Super Inductive System (SIS) Therapy With Therapeutic Exercise and Health Education in Lateral Elbow Tendinopathy","status":"NOT_YET_RECRUITING","sponsor":"University of Vic - Central University of Catalonia","startDate":"2026-03-30","conditions":"Lateral Epicondylitis (Tennis Elbow), Lateral Epicondylalgia, Lateral Elbow Tendinopathy","enrollment":224,"completionDate":"2028-09-01","primaryEndpoint":"Change in pain intensity measured with the 10-cm Visual Analog Scale (VAS)"},{"nctId":"NCT07189871","phase":"PHASE1, PHASE2","title":"177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Radiopharm Theranostics, Ltd","startDate":"2026-02-23","conditions":"Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer)","enrollment":61,"completionDate":"2027-12","primaryEndpoint":"Recommended dose(s) of 177Lu-BetaBart for future exploration (phase 1)"},{"nctId":"NCT06239480","phase":"PHASE3","title":"SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Palvella Therapeutics, Inc.","startDate":"2024-07-31","conditions":"Microcystic Lymphatic Malformation","enrollment":51,"completionDate":"2026-07","primaryEndpoint":"Overall microcystic lymphatic malformations Investigator Global Assessment (mLM-IGA)"},{"nctId":"NCT07498933","phase":"","title":"FAP-targeted PET/NIR in Lung Malignant Tumors","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-06-03","conditions":"Non-Small Cell Lung Cancer, PET/CT, Neoadjuvant Therapy","enrollment":200,"completionDate":"2027-12-31","primaryEndpoint":"Accuracy of EB-FAPI fluorescence imaging for tumor bed delineation after neoadjuvant therapy"},{"nctId":"NCT07494721","phase":"NA","title":"Effects of Training With a Pressure Cuff on Cellular Energy Activity","status":"NOT_YET_RECRUITING","sponsor":"Spital Thurgau AG","startDate":"2026-07","conditions":"Physical Deconditioning","enrollment":51,"completionDate":"2026-12","primaryEndpoint":"Determination of changes in the mitochondrial capacity of skeletal muscle (of the thigh muscle, vastus lateralis; measured non-invasively)"},{"nctId":"NCT06052267","phase":"PHASE3","title":"A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations","status":"RECRUITING","sponsor":"Teva Branded Pharmaceutical Products R&D LLC","startDate":"2023-08-30","conditions":"Asthma","enrollment":2700,"completionDate":"2026-10-31","primaryEndpoint":"Time to First Severe Clinical Asthma Exacerbation (CAE) with High Dose (HD) Fp/ABS eMDPI"},{"nctId":"NCT07494071","phase":"NA","title":"Improving Family Communication in Older Adults: A Pilot Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-04","conditions":"Intergenerational Relations","enrollment":40,"completionDate":"2028-02","primaryEndpoint":"Perceived communication competence"},{"nctId":"NCT07293676","phase":"NA","title":"IASTM and Vibration Effects on Pain, Functionality, and Kinesiophobia in Lumbar Disc Herniation","status":"RECRUITING","sponsor":"Istanbul Medipol University Hospital","startDate":"2026-01-05","conditions":"Vibration, Lumbar Disc Herniation, Soft Tissue Mobilization","enrollment":45,"completionDate":"2026-05-15","primaryEndpoint":"Visual Analog Scale"},{"nctId":"NCT04238676","phase":"PHASE1, PHASE2","title":"Persica 002 Phase 1b PP353 vs Placebo in the Treatment of Low Back Pain","status":"COMPLETED","sponsor":"Persica Pharmaceuticals Ltd","startDate":"2020-01-20","conditions":"Chronic Low-back Pain","enrollment":43,"completionDate":"2024-12-09","primaryEndpoint":"Incidence of Adverse Events"},{"nctId":"NCT05058651","phase":"PHASE2, PHASE3","title":"Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-28","conditions":"Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma, Recurrent Extrapulmonary Neuroendocrine Carcinoma","enrollment":189,"completionDate":"2028-10-01","primaryEndpoint":"Overall survival"},{"nctId":"NCT07497529","phase":"NA","title":"WhatsApp Radio Taiso Exercise Program for Adults Aged 60+","status":"RECRUITING","sponsor":"Ondokuz Mayıs University","startDate":"2026-03-10","conditions":"Older Adults (60 - 85 Years Old)","enrollment":30,"completionDate":"2026-05-31","primaryEndpoint":"WhatsApp Feedback Questions"},{"nctId":"NCT07137442","phase":"","title":"Distinguishing Tics and Functional Tics Using Clinical Neurophysiological Techniques","status":"RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2026-04-01","conditions":"Tics, Functional Tics","enrollment":75,"completionDate":"2034-08-01","primaryEndpoint":"Cortical excitability as determined by beta power at the vertex"},{"nctId":"NCT06695780","phase":"","title":"Food Typologies and Multidimensional Phenotyping of Elderly in Auvergne-Rhône-Alpes (Part'AGE)","status":"RECRUITING","sponsor":"Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement","startDate":"2025-02-03","conditions":"Nutritional Assessment, Physical Activity, Health","enrollment":1000,"completionDate":"2028-02","primaryEndpoint":"Classification of our study population into 5 dietary typologies associated with more or less successful aging"},{"nctId":"NCT03049462","phase":"PHASE1","title":"The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2017-03-13","conditions":"Polycystic Ovary Syndrome","enrollment":100,"completionDate":"2026-09-30","primaryEndpoint":"Cohorts 1 and 2: Change in BAT metabolic activity"},{"nctId":"NCT05443880","phase":"NA","title":"Exercise and Mindfulness in Patients With Non-specific Chronic Low Back Pain: The BACKFIT Project","status":"COMPLETED","sponsor":"IBS Granada","startDate":"2022-01-01","conditions":"Low Back Pain","enrollment":105,"completionDate":"2025-12-31","primaryEndpoint":"Change from baseline Muscular fitness at 2 months: The trunk muscle strength/endurance"},{"nctId":"NCT06888323","phase":"PHASE1","title":"Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-27","conditions":"Refractory Myelodysplastic Syndrome","enrollment":30,"completionDate":"2027-12-31","primaryEndpoint":"Maximum tolerated dose"},{"nctId":"NCT06096727","phase":"NA","title":"The Energize! Study for Adults With Knee Replacement","status":"COMPLETED","sponsor":"University of South Carolina","startDate":"2023-10-24","conditions":"Knee Arthroplasty","enrollment":50,"completionDate":"2024-09-10","primaryEndpoint":"Minutes of Moderate to Vigorous Intensity Physical Activity"},{"nctId":"NCT06554795","phase":"PHASE1, PHASE2","title":"First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"DualityBio Inc.","startDate":"2024-09-03","conditions":"Solid Tumor, Adult","enrollment":360,"completionDate":"2027-02","primaryEndpoint":"Phase 1/2a: Percentage of Participants with Adverse events (AE) serious AE (SAE)"},{"nctId":"NCT07309393","phase":"NA","title":"Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function","status":"RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2025-12-31","conditions":"Residual Neuromuscular Block","enrollment":240,"completionDate":"2026-06-30","primaryEndpoint":"Change in Forced Expiratory Volume in 1 Second (FEV1) from Baseline to 1 Hour Postoperatively"},{"nctId":"NCT02514564","phase":"","title":"The Effects of Aerobic Exercise in Microvascular Endothelium Function in Patients With Cardiovascular Diseases","status":"COMPLETED","sponsor":"Instituto Nacional de Cardiologia de Laranjeiras","startDate":"2014-12","conditions":"Cardiovascular Diseases","enrollment":115,"completionDate":"2016-12","primaryEndpoint":"Changes in Skin microvascular blood flow"},{"nctId":"NCT05988203","phase":"PHASE1, PHASE2","title":"A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2023-09-21","conditions":"Monkeypox","enrollment":96,"completionDate":"2026-03-04","primaryEndpoint":"SSA, SSB, and SSD - Proportion (%) of participants reporting solicited local reactions at the injection site (pain, erythema/redness, induration/swelling)"},{"nctId":"NCT07496710","phase":"","title":"Relationship Between Nutritional Status, Physical Activity and Periodontal Status","status":"COMPLETED","sponsor":"Universidad Rey Juan Carlos","startDate":"2021-11-03","conditions":"Periodontitis, Cardiovascular Risk Factor, Metabolic Risk Factors","enrollment":61,"completionDate":"2022-06-30","primaryEndpoint":"Periodontal status"},{"nctId":"NCT05562427","phase":"NA","title":"Program for Fully Understanding Eating and Lifestyle Change (FUEL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Miriam Hospital","startDate":"2022-10-31","conditions":"Obesity","enrollment":150,"completionDate":"2027-04-30","primaryEndpoint":"Change in dietary lapses"},{"nctId":"NCT06186869","phase":"NA","title":"Effects of Two Different Exercise Programs and Diet in Obese Subjects With NAFLD","status":"RECRUITING","sponsor":"Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis","startDate":"2023-10-02","conditions":"Obesity, NAFLD","enrollment":90,"completionDate":"2026-12-23","primaryEndpoint":"The effect of diet and exercise on systemic inflammatory status"},{"nctId":"NCT06527872","phase":"","title":"Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-10-04","conditions":"Lupus Nephritis","enrollment":300,"completionDate":"2029-03-29","primaryEndpoint":"Number of Participants Maintaining Renal Function (Less than Equal to [<=] 30 Percentage [%] Decline in Estimated Glomerular Filtration Rate [eGFR] from the Initiation of Belimumab) and Not Requiring "},{"nctId":"NCT03233711","phase":"PHASE3","title":"Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-07-05","conditions":"Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Margin Squamous Cell Carcinoma","enrollment":344,"completionDate":"2027-12-31","primaryEndpoint":"Disease free survival"},{"nctId":"NCT07290036","phase":"PHASE1","title":"A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults","status":"RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2025-12-10","conditions":"Psoriatic Arthritis, Axial Spondyloarthritis","enrollment":392,"completionDate":"2028-07-04","primaryEndpoint":"Steady-state Trough Concentration (Ctrough,ss) at Week 16"},{"nctId":"NCT07494357","phase":"NA","title":"Effects of Dual Task-Oriented Circuit Training on Walking Recovery in Sub-acute Stroke","status":"NOT_YET_RECRUITING","sponsor":"Universitas Padjadjaran","startDate":"2026-04-01","conditions":"Stroke, Cerebrovascular","enrollment":36,"completionDate":"2026-08-30","primaryEndpoint":"Adherence Rate"},{"nctId":"NCT07407569","phase":"PHASE2","title":"Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination","status":"RECRUITING","sponsor":"Universiteit Antwerpen","startDate":"2026-03-25","conditions":"Human Papilloma Virus Infection Type 16","enrollment":50,"completionDate":"2029-01-01","primaryEndpoint":"Detection of HPV16 E1^E4 spliced mRNA in an in vitro infection model using first-void urine samples"},{"nctId":"NCT07495852","phase":"PHASE3","title":"Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant","status":"RECRUITING","sponsor":"Glaukos Corporation","startDate":"2026-02-17","conditions":"Glaucoma","enrollment":510,"completionDate":"2032-03","primaryEndpoint":"Intraocular pressure (IOP)"},{"nctId":"NCT07482553","phase":"","title":"Antibiofilm Activity of Chitosan Nanoparticles Against Uropathogenic Escherichia Coli","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-05-01","conditions":"Urinary Tract Infections (UTIs), Catheter-Associated Urinary Tract Infections (CAUTIs), Biofilm Formation by Uropathogenic Escherichia Coli (UPEC)","enrollment":60,"completionDate":"2027-06","primaryEndpoint":"Percentage of biofilm inhibition of UPEC isolates by chitosan nanoparticles alone and in combination with ciprofloxacin"},{"nctId":"NCT03076554","phase":"PHASE2","title":"A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-19","conditions":"Thymoma, Thymic Carcinoma","enrollment":56,"completionDate":"2027-06-30","primaryEndpoint":"Safety and tolerability of Avelumab based on NCI-CTCAE v4.0"},{"nctId":"NCT07497750","phase":"NA","title":"Impact of Artificial Intelligence Algorithm-driven Versus Standard Lifestyle Intervention in Non-Alcoholic Fatty Liver Disease - A Multicenter, Randomized, Open-label, Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2026-06-01","conditions":"Non Alcoholic Fatty Liver Disease","enrollment":216,"completionDate":"2030-12-31","primaryEndpoint":"Proportion of participants with a relative decline of at least 30% in liver fat"},{"nctId":"NCT06072183","phase":"PHASE3","title":"A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-11-08","conditions":"Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo","enrollment":1571,"completionDate":"2027-07-30","primaryEndpoint":"US only Co-Primary Endpoints: Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52 and Total body Vitiligo Area Scoring Index 50 (T-VASI50) at Week 52"},{"nctId":"NCT07496749","phase":"NA","title":"KD Treatment for Super-refractory Status Epilepticus","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2025-10-20","conditions":"Super-refractory Status Epilepticus","enrollment":84,"completionDate":"2027-03-01","primaryEndpoint":"Time to cessation of SRSE"},{"nctId":"NCT03954210","phase":"NA","title":"SIESTA: Sleep Intervention to Enhance Cognitive Status and Reduce Beta Amyloid","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2019-08-27","conditions":"Insomnia","enrollment":200,"completionDate":"2025-04-18","primaryEndpoint":"Continuous Performance Test (CPT)"},{"nctId":"NCT04436640","phase":"PHASE3","title":"A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2020-06-16","conditions":"Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpa","enrollment":508,"completionDate":"2026-08-07","primaryEndpoint":"Percentage of participants with treatment-emergent adverse events (TEAEs) during the study"},{"nctId":"NCT07495917","phase":"NA","title":"Tetris Intervention Following Subliminal Reactivation for Intrusive Memories","status":"NOT_YET_RECRUITING","sponsor":"Shaanxi Normal University","startDate":"2026-03-27","conditions":"Post-traumatic Stress Disorder (PTSD), Intrusive Memories of Traumatic Event(s)","enrollment":123,"completionDate":"2027-06-30","primaryEndpoint":"Number of trauma-related intrusive memories"},{"nctId":"NCT07037771","phase":"PHASE3","title":"A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)","status":"RECRUITING","sponsor":"Arrowhead Pharmaceuticals","startDate":"2025-06-17","conditions":"Homozygous Familial Hypercholesterolemia","enrollment":60,"completionDate":"2027-08-20","primaryEndpoint":"Percent Change from Baseline to Month 12 in Fasting Low Density Lipoprotein Cholesterol (LDL-C) (Randomized period)"},{"nctId":"NCT07266831","phase":"PHASE2, PHASE3","title":"A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-18","conditions":"Human Immunodeficiency Virus Type 1 (HIV-1) Infection","enrollment":570,"completionDate":"2030-04-03","primaryEndpoint":"Phase 2: Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/mL at Week 24"},{"nctId":"NCT01809288","phase":"","title":"Identifying Risk for Diabetes and Heart Disease in Women","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2013-09-26","conditions":"Obesity, Insulin Resistance, Triglycerides","enrollment":146,"completionDate":"","primaryEndpoint":"Determine if there are differences in African, African-American and white women in the relationship between triglyceride levels, (a frequently used screening test for diabetes and heart disease) gluco"},{"nctId":"NCT05531565","phase":"PHASE2, PHASE3","title":"A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus","status":"RECRUITING","sponsor":"Biogen","startDate":"2022-09-13","conditions":"Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus","enrollment":450,"completionDate":"2027-12-14","primaryEndpoint":"Parts A: Percentage of Participants who Achieve a Cutaneous Lupus Activity of Physician's Global Assessment-Revised (CLA-IGA-R) Erythema Score of 0 or 1"},{"nctId":"NCT07316985","phase":"","title":"Efficacy of Physical Fitness Training Combined With Exercise Therapy on Gait in Children With Cerebral Palsy","status":"COMPLETED","sponsor":"LiNa Zhang","startDate":"2023-06-01","conditions":"Spastic Cerebral Palsy","enrollment":72,"completionDate":"2024-12-31","primaryEndpoint":"Change in Step Time"},{"nctId":"NCT07482501","phase":"NA","title":"Repetitive Transcranial Magnetic Stimulation in Cardiac Autonomic Dysfunction","status":"RECRUITING","sponsor":"Afyonkarahisar Health Sciences University","startDate":"2026-03-26","conditions":"Stroke, Autonomic Dysfunction, Hemiparesis","enrollment":44,"completionDate":"2026-09-15","primaryEndpoint":"Change from Baseline in Heart Rate Variability (HRV) Assessment at the 4th week"},{"nctId":"NCT07497646","phase":"NA","title":"Repeated Bilateral Greater Occipital Nerve Blockade in Chronic Migraine and Chronic Tension-Type Headache","status":"COMPLETED","sponsor":"Saglik Bilimleri Universitesi","startDate":"2025-01-01","conditions":"Chronic Migraine Headache, Chronic Tension-type Headache","enrollment":290,"completionDate":"2025-09-30","primaryEndpoint":"Change from baseline in monthly number of headache days assessed using patient-reported daily headache diary"},{"nctId":"NCT07293559","phase":"","title":"Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States","status":"RECRUITING","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2026-02-24","conditions":"HIV-1-infection, Breastfeeding, Pregnancy Related","enrollment":1150,"completionDate":"2031-04-24","primaryEndpoint":"CA 1: Factors influencing infant feeding decision"},{"nctId":"NCT07424547","phase":"PHASE1","title":"Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Conjupro Biotherapeutics, Inc.","startDate":"2026-03-03","conditions":"Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer","enrollment":386,"completionDate":"2030-04","primaryEndpoint":"Assessment of the MTD and/or RP2D (recommended Phase II dose) (Phase 1a)."},{"nctId":"NCT05460676","phase":"NA","title":"Reducing Tobacco Smoking: a Transcranial Direct Current Stimulation (TDCS) Telehealth Study","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2023-08-15","conditions":"Smoking Cessation","enrollment":46,"completionDate":"2026-04","primaryEndpoint":"Feasibility and Tolerability Questionnaire (FTQ) score"},{"nctId":"NCT03109288","phase":"PHASE1, PHASE2","title":"Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-08-11","conditions":"Multiple Sclerosis","enrollment":250,"completionDate":"2029-01-01","primaryEndpoint":"Primary outcome will be change in CombiWISE progression rate at the end of monotherapy plus combination therapy period in comparison to projected baseline disability progression."},{"nctId":"NCT05909202","phase":"NA","title":"A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients","status":"RECRUITING","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2024-06-05","conditions":"Neoplasm, Caregivers","enrollment":218,"completionDate":"2029-09-01","primaryEndpoint":"Changes in perceived stress"},{"nctId":"NCT04785820","phase":"PHASE2","title":"A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-06-25","conditions":"Advanced or Metastatic Esophageal Squamous Cell Carcinoma","enrollment":190,"completionDate":"2025-01-30","primaryEndpoint":"Overall Survival (OS)"},{"nctId":"NCT07488559","phase":"NA","title":"Engage Coaching (R33 Phase)","status":"NOT_YET_RECRUITING","sponsor":"University of Rochester","startDate":"2026-05-15","conditions":"Social Connection, Loneliness, Suicide Ideation","enrollment":120,"completionDate":"2028-12-31","primaryEndpoint":"Loneliness"},{"nctId":"NCT04123795","phase":"PHASE3","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2020-01-21","conditions":"Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis, Mixed Guttate/Plaque Psoriasis","enrollment":49,"completionDate":"2034-08-15","primaryEndpoint":"Plasma concentrations of Certolizumab pegol (CZP) at Week 16"},{"nctId":"NCT05840159","phase":"PHASE4","title":"A Study of Doxycycline to Treat Chlamydial Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-01-19","conditions":"Chlamydial Infection","enrollment":526,"completionDate":"2026-02-12","primaryEndpoint":"Proportion of assigned men participants with microbiologic cure as detected via rectal swab"},{"nctId":"NCT01829724","phase":"","title":"Cerebral Palsy and the Study of Brain Activity During Motor Tasks","status":"RECRUITING","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2013-08-22","conditions":"Cerebral Palsy, Children","enrollment":320,"completionDate":"","primaryEndpoint":"changes in brain activation and motor performance in childhood-onset brain injury before and after a short training program."},{"nctId":"NCT04223791","phase":"PHASE3","title":"Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-18","conditions":"HIV Infection","enrollment":643,"completionDate":"2025-02-27","primaryEndpoint":"Percentage of Participants With Human Immunodeficiency Virus 1 Ribonucleic Acid (HIV-1 RNA) ≥50 Copies/mL at Week 48"},{"nctId":"NCT07494409","phase":"PHASE3","title":"A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia","status":"RECRUITING","sponsor":"Kind Pharmaceuticals LLC","startDate":"2025-10-31","conditions":"Anemia Due to Chronic Kidney Disease","enrollment":300,"completionDate":"2027-04-30","primaryEndpoint":"Evaluate the efficacy of AND017 compared with the active control in maintaining Hb levels in anemic patients with ESKD"},{"nctId":"NCT03844061","phase":"PHASE2","title":"Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2019-07-29","conditions":"Systemic Sclerosis","enrollment":30,"completionDate":"2026-06-30","primaryEndpoint":"Primary Efficacy Outcome: Change in the ACR Revised CRISS at 12 months"},{"nctId":"NCT07498686","phase":"","title":"Plasma a-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Neurodegeneration Disease","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2023-05-01","conditions":"RT-QuIC","enrollment":458,"completionDate":"2026-12-23","primaryEndpoint":"slope"},{"nctId":"NCT06299319","phase":"PHASE1","title":"Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2024-09-01","conditions":"Obsessive-Compulsive Disorder","enrollment":10,"completionDate":"2026-08","primaryEndpoint":"Feasibility of administering psilocybin (25 mg) in adults with treatment-resistant OCD"},{"nctId":"NCT07459166","phase":"PHASE2","title":"A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade","status":"NOT_YET_RECRUITING","sponsor":"Clear Scientific, Inc.","startDate":"2026-04","conditions":"Fentanyl Overdose, Fentanyl Poisoning","enrollment":16,"completionDate":"2026-10","primaryEndpoint":"Number of participants with CS-1103-related adverse events (AEs) assessed by physical examinations"},{"nctId":"NCT07495137","phase":"NA","title":"The Improvement Effect of Real-time Artificial Intelligence Assisted Identification of Bleeding Points on Hemostasis Efficiency in Endoscopic Submucosal Dissection","status":"NOT_YET_RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2026-03-31","conditions":"Endoscopic Submucosal Dissection, Endoscopic Submucosal Dissection (ESD)","enrollment":160,"completionDate":"2027-12-31","primaryEndpoint":"Average single hemostasis time"},{"nctId":"NCT07496554","phase":"NA","title":"Long-term Effects of Early Shoulder Exercise After CIED Implantation","status":"COMPLETED","sponsor":"Erzincan Binali Yildirim Universitesi","startDate":"2021-02-01","conditions":"Cardiac Implantable Electronic Device (CIED), Shoulder Dysfunction","enrollment":89,"completionDate":"2026-03-23","primaryEndpoint":"Shoulder Range of Motion (ROM) - Flexion and Abduction"},{"nctId":"NCT06279377","phase":"NA","title":"Examining the Effectiveness of Exercise Training After Cervical Laminoplasty Surgery","status":"COMPLETED","sponsor":"Izmir Katip Celebi University","startDate":"2023-05-05","conditions":"Cervical Spine Disease, Surgery, Rehabilitation","enrollment":32,"completionDate":"2025-12-19","primaryEndpoint":"Pain intensity"},{"nctId":"NCT07497685","phase":"NA","title":"Effects of Different Caffeine Forms on Aerobic and Anaerobic Exercise Performance","status":"COMPLETED","sponsor":"University of Gaziantep","startDate":"2024-10-10","conditions":"Exercise Performance, Physical Performance","enrollment":14,"completionDate":"2025-03-10","primaryEndpoint":"Aerobic Capacity (VO2max)"},{"nctId":"NCT07494292","phase":"NA","title":"Personalised Active Self-management of Sleep Apnea Program","status":"NOT_YET_RECRUITING","sponsor":"Hong Kong Metropolitan University","startDate":"2026-04-01","conditions":"Obstructive Sleep Apnea (OSA)","enrollment":60,"completionDate":"2027-03-31","primaryEndpoint":"PAP uptake"},{"nctId":"NCT04849728","phase":"PHASE3","title":"A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inventiva Pharma","startDate":"2021-08-19","conditions":"NASH - Nonalcoholic Steatohepatitis","enrollment":1000,"completionDate":"2026-12-30","primaryEndpoint":"Resolution of NASH and improvement of fibrosis"},{"nctId":"NCT07431151","phase":"NA","title":"Effects of Intensive Virtual Reality-Based Balance and Gait Training on Activity Performance and Quality of Life in Subacute Stroke Patients","status":"RECRUITING","sponsor":"Ankara Yildirim Beyazıt University","startDate":"2026-02-01","conditions":"Stroke","enrollment":48,"completionDate":"2026-12-31","primaryEndpoint":"Timed Up and Go Test"},{"nctId":"NCT07046494","phase":"PHASE2","title":"Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder","status":"RECRUITING","sponsor":"Rapport Therapeutics Inc.","startDate":"2025-07-25","conditions":"Bipolar 1 Disorder","enrollment":224,"completionDate":"2026-12","primaryEndpoint":"Young Mania Rating Scale (YMRS)"},{"nctId":"NCT05642195","phase":"PHASE1, PHASE2","title":"Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung","enrollment":30,"completionDate":"2035-12-30","primaryEndpoint":"Phase II Component: To assess the frequency of immunologic responses to purified CT-X and autosomal CT antigens in NSCLC participants following vaccinations with H1299 cancer cell lysate and Montanide"},{"nctId":"NCT06912633","phase":"PHASE2","title":"Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)","status":"RECRUITING","sponsor":"jCyte, Inc","startDate":"2025-06-20","conditions":"Retinitis Pigmentosa","enrollment":60,"completionDate":"2026-09","primaryEndpoint":"Safety of Intravitreal Injection of 6.0M jCell"},{"nctId":"NCT07495943","phase":"NA","title":"Effects of 2-Aticyto Complex and D-Ribose on Pain and Clinical Course in Patients With Fibromyalgia","status":"NOT_YET_RECRUITING","sponsor":"Haydarpasa Numune Training and Research Hospital","startDate":"2026-05-04","conditions":"Fibromyalgia Syndrome, Fibromyalgia","enrollment":200,"completionDate":"2027-05-04","primaryEndpoint":"Change in Pain Intensity Measured by Numeric Rating Scale (NRS)"},{"nctId":"NCT07495891","phase":"NA","title":"Sustainability of the Effects of an Adapted Physical Activity Program on Physical Fitness and Psycho-behavioral Factors in Patients With Chronic Diseases","status":"NOT_YET_RECRUITING","sponsor":"Hopital La Musse","startDate":"2026-03-30","conditions":"Adapted Physical Activity, Smartwatches, Chronic Disease","enrollment":280,"completionDate":"2028-12-31","primaryEndpoint":"Improvements in physical fitness and anthropometric parameters"},{"nctId":"NCT06009926","phase":"PHASE2","title":"Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-12-04","conditions":"Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Occupational Malignant Neoplasm","enrollment":72,"completionDate":"2027-11-01","primaryEndpoint":"Change in total amount of acetaminophen mercapturate excreted in the urine"},{"nctId":"NCT07495410","phase":"NA","title":"Anderson-Fabry Disease Fitness Improvement Training: A-FAD-FIT","status":"ENROLLING_BY_INVITATION","sponsor":"General University Hospital, Prague","startDate":"2025-10-06","conditions":"Fabry Disease","enrollment":15,"completionDate":"2028-06-30","primaryEndpoint":"Change in cardiorespiratory fitness"},{"nctId":"NCT02107989","phase":"","title":"Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database","status":"RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2014-03-11","conditions":"Epilepsy","enrollment":700,"completionDate":"2028-03-30","primaryEndpoint":"All outcomes in this study are Exploratory."},{"nctId":"NCT07490548","phase":"","title":"Lifestyle Medicine Adherence, Mental Wellbeing, and Quality of Life in Pediatric Oncology in Ecuador","status":"ENROLLING_BY_INVITATION","sponsor":"Universidad de Especialidades Espiritu Santo","startDate":"2025-05-01","conditions":"Childhood Cancer Survivors","enrollment":62,"completionDate":"2027-04-30","primaryEndpoint":"Prevalence, time trends, and correlation factors between the adherence to the six pillars of lifestyle medicine on HRQoL and mental wellbeing"},{"nctId":"NCT06865183","phase":"NA","title":"Investigating a Brief Virtual Seminar Series for Parents of Children Ages 2-12","status":"ACTIVE_NOT_RECRUITING","sponsor":"Texas Tech University","startDate":"2024-02-23","conditions":"Positive Parenting Skills","enrollment":123,"completionDate":"2026-07-14","primaryEndpoint":"Parent Satisfaction"},{"nctId":"NCT07496528","phase":"NA","title":"Acupuncture for Colorectal sUrgery Recovery Enhancement: A Randomized Controlled Trial Evaluating Gastrointestinal Functional Recovery After Minimally Invasive Resection","status":"NOT_YET_RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2026-04-01","conditions":"Colorectal Neoplasms, Ileus Postoperative, Postoperative Complication","enrollment":240,"completionDate":"2029-05-31","primaryEndpoint":"Time to First Postoperative Defecation"},{"nctId":"NCT06624228","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2024-10-21","conditions":"Psoriatic Arthritis","enrollment":684,"completionDate":"2026-05-26","primaryEndpoint":"American College of Rheumatology 50 (ACR50) at Week 16"},{"nctId":"NCT06865196","phase":"NA","title":"Investigating a Brief Virtual Seminar Series for Parents of Teens Ages 13-17","status":"ACTIVE_NOT_RECRUITING","sponsor":"Texas Tech University","startDate":"2024-10-17","conditions":"Positive Parenting Skills","enrollment":185,"completionDate":"2026-07-14","primaryEndpoint":"Parent Satisfaction"},{"nctId":"NCT04781387","phase":"PHASE2","title":"Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection","status":"COMPLETED","sponsor":"Crestone, Inc","startDate":"2021-01-05","conditions":"Clostridioides Difficile Infection","enrollment":43,"completionDate":"2024-04-16","primaryEndpoint":"Rate of Clinical Cure at the Test of Cure [TOC] Visit in the Intent-to-treat [ITT] Population"},{"nctId":"NCT06223516","phase":"PHASE1","title":"Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2024-06-17","conditions":"Multiple Myeloma","enrollment":60,"completionDate":"2027-12","primaryEndpoint":"Percentage of Participants Experiencing Cytokine Release Syndrome (CRS) Events"},{"nctId":"NCT07495033","phase":"PHASE3","title":"Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease","status":"NOT_YET_RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2026-03-01","conditions":"CTD-ILD","enrollment":260,"completionDate":"2030-05-31","primaryEndpoint":"Change from Baseline in FVC(mL) at Week 52"},{"nctId":"NCT06602141","phase":"NA","title":"Assessments of Adipogenesis, Lipid Turnover and Cellular Composition in Adipose Tissue in Response to Endurance Exercise","status":"RECRUITING","sponsor":"AdventHealth Translational Research Institute","startDate":"2024-09-11","conditions":"Obesity","enrollment":70,"completionDate":"2029-04","primaryEndpoint":"In vivo adipogenesis"},{"nctId":"NCT07117916","phase":"NA","title":"STRONGER 60+: Assessing the Clinical Effectiveness and Delivery of an Adapted FINGER Model for Brain Health in Primary Care","status":"NOT_YET_RECRUITING","sponsor":"Karolinska Institutet","startDate":"2026-08-01","conditions":"Older Adults at High Risk for MCI, Older Adults With Mild to Moderate Level of Dementia","enrollment":80,"completionDate":"2028-08","primaryEndpoint":"Composite healthy lifestyle score"},{"nctId":"NCT07219719","phase":"PHASE1","title":"Temporal Interference for Thalamocortical Activity and Network Modulation","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2025-12-01","conditions":"Healthy Participants","enrollment":30,"completionDate":"2027-11","primaryEndpoint":"Change in thalamocortical functional connectivity (FC): resting state fMRI"},{"nctId":"NCT05753501","phase":"PHASE1","title":"Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-06-09","conditions":"Hematologic Cancer","enrollment":135,"completionDate":"2031-03","primaryEndpoint":"Number of Participants with Adverse Events (AE)"},{"nctId":"NCT06435312","phase":"PHASE3","title":"An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis","status":"ENROLLING_BY_INVITATION","sponsor":"UCB Biopharma SRL","startDate":"2024-11-19","conditions":"Generalized Myasthenia Gravis","enrollment":8,"completionDate":"2027-11-19","primaryEndpoint":"Occurence of treatment emergent adverse events during the course of the study"},{"nctId":"NCT06923800","phase":"NA","title":"Exercise Interventions and Dietary Advice in Fibromyalgia and IBS","status":"RECRUITING","sponsor":"Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis","startDate":"2025-04-14","conditions":"Fibromyalgia, Irritable Bowel Syndrome","enrollment":30,"completionDate":"2028-12","primaryEndpoint":"Fibromyalgia symptom assesment"},{"nctId":"NCT02595944","phase":"PHASE3","title":"Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-07-22","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7","enrollment":903,"completionDate":"2026-12-31","primaryEndpoint":"Disease-free survival (DFS)"},{"nctId":"NCT01187368","phase":"NA","title":"Prospective Multi-Center Randomized Study for Evaluating the EVAHEART®2 Left Ventricular Assist System","status":"SUSPENDED","sponsor":"Evaheart, Inc.","startDate":"2020-03-31","conditions":"Heart Failure","enrollment":399,"completionDate":"2028-07-31","primaryEndpoint":"Short-Term Primary Endpoint"},{"nctId":"NCT04303780","phase":"PHASE3","title":"Study to Compare AMG 510 \"Proposed INN Sotorasib\" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2020-06-04","conditions":"KRAS p, G12c Mutated /Advanced Metastatic NSCLC","enrollment":345,"completionDate":"2026-05-29","primaryEndpoint":"Progression-free Survival (PFS)"},{"nctId":"NCT06294119","phase":"NA","title":"Multivariate Approach to the Numerical Assessment of Cortical - Autonomic - VAscular Dynamic Interplay","status":"RECRUITING","sponsor":"IRCCS Policlinico S. Donato","startDate":"2025-09-30","conditions":"Cardiac Disease, Depression","enrollment":80,"completionDate":"2029-02-28","primaryEndpoint":"Autoregulation index (ARI)"},{"nctId":"NCT07486037","phase":"NA","title":"Caring for Caregivers","status":"RECRUITING","sponsor":"Indiana University","startDate":"2026-03-01","conditions":"Intervention Group, Treatment as Usual","enrollment":25,"completionDate":"2028-06-01","primaryEndpoint":"Physical Activity"},{"nctId":"NCT07496203","phase":"NA","title":"The Effectiveness of BETY in Knee Osteoarthritis With Intra-Articular Injections","status":"RECRUITING","sponsor":"Hacettepe University","startDate":"2026-01-02","conditions":"Osteo Arthritis of the Knee, Pain, Pain Management","enrollment":60,"completionDate":"2027-12","primaryEndpoint":"BETY-BQ"},{"nctId":"NCT07236554","phase":"NA","title":"Blood Flow Restriction Training Versus Mulligan Technique in Treatment of Lateral Epicondylitis","status":"COMPLETED","sponsor":"Cairo University","startDate":"2025-09-15","conditions":"Lateral Epicondylitis (Tennis Elbow)","enrollment":45,"completionDate":"2026-03-15","primaryEndpoint":"Grip strength"},{"nctId":"NCT07496827","phase":"","title":"Detection of Parasitic Infections in Patients With Haematological Disorders in Assiut University Hospitals","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-04","conditions":"Haematological Disorders","enrollment":285,"completionDate":"2027-12","primaryEndpoint":"Toxoplasma gondii seroprevalence"},{"nctId":"NCT07494591","phase":"NA","title":"TEAS for Ipsilateral Shoulder Pain After Video-Assisted Thoracoscopic Lung Surgery","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2026-04-01","conditions":"Ipsilateral Shoulder Pain, Video-Assisted Thoracoscopic Surgery","enrollment":216,"completionDate":"2026-12-30","primaryEndpoint":"Incidence of Ipsilateral Shoulder Pain (ISP) with Shoulder Movement at 24 Hours Postoperatively"},{"nctId":"NCT07469527","phase":"NA","title":"Effects of Feel Free® Classic Tonic on Stress and Pharmacokinetics in Healthy Adults","status":"RECRUITING","sponsor":"Botanic Tonics, LLC","startDate":"2026-03-07","conditions":"Anxiety, Physiological Stress, Stress","enrollment":165,"completionDate":"2026-10-14","primaryEndpoint":"Change in Perceived Stress Scale-10 (PSS-10) Score"},{"nctId":"NCT00032513","phase":"","title":"Genetic Studies of Chronic Active Epstein-Barr Disease","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-04-16","conditions":"Chronic Active Epstein-Barr Virus","enrollment":300,"completionDate":"","primaryEndpoint":"The primary goal of this study is to identify genetic mutations responsible for CAEBV."},{"nctId":"NCT07244991","phase":"NA","title":"Effect of MI Paste Plus™ on Streptococcus Mutans and White Spot Lesions in Fixed Orthodontics","status":"RECRUITING","sponsor":"Cardenal Herrera University","startDate":"2026-01-04","conditions":"Dental Caries, Streptococcus Mutans, Tooth Demineralization","enrollment":200,"completionDate":"2027-11","primaryEndpoint":"Change in salivary Streptococcus mutans count (log₁₀ CFU/mL)"},{"nctId":"NCT05315492","phase":"NA","title":"Strengthening Community Addiction Services in Vietnam","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2024-04-17","conditions":"Addiction, Opioid","enrollment":1620,"completionDate":"2026-02-28","primaryEndpoint":"PWUD's STTR fulfillment score"},{"nctId":"NCT06549452","phase":"NA","title":"Mobile Health Intervention to Improve Exercise in Pediatric PH","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2024-12-01","conditions":"Pulmonary Arterial Hypertension","enrollment":50,"completionDate":"2030-11-01","primaryEndpoint":"Change in average daily step count from baseline to 12 weeks"},{"nctId":"NCT07494253","phase":"NA","title":"Effects of Reducose on Postprandial Glycemic Levels in Obese Children and Adolescents","status":"ENROLLING_BY_INVITATION","sponsor":"University of Bari Aldo Moro","startDate":"2025-06-01","conditions":"Obesity","enrollment":80,"completionDate":"2026-06-30","primaryEndpoint":"Area Under the Curve for Plasma Glucose"},{"nctId":"NCT04449549","phase":"PHASE2","title":"Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-08-24","conditions":"Neoplasms","enrollment":82,"completionDate":"2026-04-08","primaryEndpoint":"Objective response"},{"nctId":"NCT05353049","phase":"NA","title":"How to Bathe a Person With Dementia? A Bathing Intervention Based on Basale Stimulation® for People With Moderate to Severe Dementia","status":"COMPLETED","sponsor":"University of Salamanca","startDate":"2021-11-01","conditions":"Patient Engagement, Behavioral Symptoms","enrollment":50,"completionDate":"2023-05-31","primaryEndpoint":"Frequency of Engagement Behaviour assessed with the Involvement Register (RIE)"},{"nctId":"NCT07292480","phase":"NA","title":"Monthly Monitoring of Plasma NfL in Treated Relapsing-remitting Multiple Sclerosis to Detect Persistent Infraclinical Disease Activity","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2025-12-12","conditions":"Multiple Sclerosis (MS) - Relapsing-remitting","enrollment":84,"completionDate":"2030-12","primaryEndpoint":"Time to evidence of disease activity between groups"},{"nctId":"NCT06875102","phase":"NA","title":"Fatigue in Sjögren's Syndrome: 3 Therapeutic Strategies","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2026-03-24","conditions":"Sjogren Syndrome","enrollment":174,"completionDate":"2028-04","primaryEndpoint":"Change in fatigue score assessed"},{"nctId":"NCT05470010","phase":"NA","title":"Smartphone App-Based Mindfulness Intervention for French and English Speaker Cancer Survivors","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2025-03-07","conditions":"Cancer, Psychological","enrollment":345,"completionDate":"2026-12-31","primaryEndpoint":"Calgary Symptoms of Stress Inventory (C-SOSI)"},{"nctId":"NCT06132256","phase":"PHASE2","title":"MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Syndax Pharmaceuticals","startDate":"2023-12-11","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":145,"completionDate":"2026-11","primaryEndpoint":"Annualized rate of decline in morning pre-dose trough forced vital capacity (FVC) (milliliter [mL])"},{"nctId":"NCT06123182","phase":"NA","title":"Guided Episodic Future Thinking to Increase Physical Activity Adherence and Promote Healthy Brain Aging","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2024-02-23","conditions":"Exercise Training, Aging","enrollment":160,"completionDate":"2027-05","primaryEndpoint":"Adherence to HIIT exercise"},{"nctId":"NCT05226117","phase":"PHASE2","title":"Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2022-03-23","conditions":"Urothelial Carcinoma","enrollment":44,"completionDate":"2025-09-24","primaryEndpoint":"Pathological complete response"},{"nctId":"NCT07410000","phase":"NA","title":"Ultrasound-Guided Quadro-Iliac Plane Block for Pain Management After Total Hip Arthroplasty","status":"RECRUITING","sponsor":"Bursa City Hospital","startDate":"2026-03-16","conditions":"Pain Management, Total Hip Arthroplasty","enrollment":100,"completionDate":"2027-03-15","primaryEndpoint":"Postoperative 24-Hour Morphine PCA Consumption"},{"nctId":"NCT05727930","phase":"NA","title":"Variable Intensive Early Walking Post-Stroke - 2 (VIEWS-2)","status":"RECRUITING","sponsor":"Indiana University","startDate":"2023-01-11","conditions":"Stroke","enrollment":100,"completionDate":"2028-10-15","primaryEndpoint":"Changes in 6 minute walk test"},{"nctId":"NCT05454566","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety, Tolerability, and Activity of ICM-203 in Subjects With Knee Osteoarthritis.","status":"NOT_YET_RECRUITING","sponsor":"ICM Co. Ltd.","startDate":"2026-11-15","conditions":"Osteoarthritis, Knee","enrollment":18,"completionDate":"2028-11-15","primaryEndpoint":"Treatment-Emergent Adverse Events (TEAEs)"},{"nctId":"NCT02954874","phase":"PHASE3","title":"Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-18","conditions":"Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7","enrollment":1155,"completionDate":"2026-05-31","primaryEndpoint":"Invasive disease-free survival (IDFS)"},{"nctId":"NCT07457437","phase":"NA","title":"Function and Lean Mass Preservation With Resistance Exercise During a GLP-1RA Treatment","status":"RECRUITING","sponsor":"University of Exeter","startDate":"2026-04-01","conditions":"Muscle Mass and Strength, Obesity & Overweight, Physical Function","enrollment":60,"completionDate":"2027-12-01","primaryEndpoint":"Skeletal Muscle Mass"},{"nctId":"NCT03737981","phase":"PHASE3","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-01-31","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":465,"completionDate":"2026-12-29","primaryEndpoint":"Progression-free Survival (PFS)"},{"nctId":"NCT04864314","phase":"NA","title":"Assessment of TetraSOD® Efficacy to Improve Semen Parameters in Men With Idiopathic Infertility","status":"COMPLETED","sponsor":"Fitoplancton Marino, S.L.","startDate":"2021-05-12","conditions":"Infertility, Male","enrollment":80,"completionDate":"2024-10-31","primaryEndpoint":"Sperm Progressive Motility"},{"nctId":"NCT07498530","phase":"NA","title":"Virtual Assistant for Exercise Adherence in Older ADULTS","status":"RECRUITING","sponsor":"University of Valencia","startDate":"2026-02-01","conditions":"Older Adult, Exercise, Adherence","enrollment":70,"completionDate":"2026-12-31","primaryEndpoint":"Exercise Adherence (% of prescribed sessions completed)"},{"nctId":"NCT06743529","phase":"NA","title":"Immediate Versus Substantiated Antibiotic Therapy in Suspected Non-Severe Ventilator-Associated Pneumonia","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2025-11-11","conditions":"Ventilator-Associated Pneumonia (VAP)","enrollment":686,"completionDate":"2029-02-11","primaryEndpoint":"Proportion of patients who die whithin 28 days or are still on invasive mechanical ventilation on day 28"},{"nctId":"NCT06561776","phase":"","title":"Investigation of Physical Impairments in Young Adults","status":"COMPLETED","sponsor":"Izmir Democracy University","startDate":"2023-09-01","conditions":"Adult Children","enrollment":51,"completionDate":"2025-05-01","primaryEndpoint":"Cough strength"},{"nctId":"NCT06114264","phase":"NA","title":"Multimodal Intervention in Patients With Non-specific Chronic Low Back Pain: the HEALTHY BACK Project","status":"COMPLETED","sponsor":"IBS Granada","startDate":"2023-01-01","conditions":"Pain, Chronic, Neurologic Manifestations, Back Pain","enrollment":70,"completionDate":"2025-04-30","primaryEndpoint":"Change from baseline Conditioned Pain Modulation (CPM) in the lower back at 2 months"},{"nctId":"NCT06577454","phase":"NA","title":"Measuring the Effects of Neurostimulation on Risky and Ambiguous Decision-Making Capacity in People With and Without Substance Use Disorder","status":"SUSPENDED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2026-04-01","conditions":"Opioid Use Disorder, Healthy Volunteers","enrollment":60,"completionDate":"2027-08-06","primaryEndpoint":"Determine neural correlates of risk and ambiguity tolerance in healthy controls and people with OUD."},{"nctId":"NCT07159074","phase":"PHASE2","title":"Repurposing Tilmanocept for Cardiac Sarcoidosis","status":"RECRUITING","sponsor":"Duke University","startDate":"2025-09-17","conditions":"Cardiac Sarcoidosis","enrollment":15,"completionDate":"2026-12-31","primaryEndpoint":"Correlation between the cardiac segments with tilmanocept uptake and the cardiac segments with fluorodeoxyglucose (FDG) uptake on cardiac PET-CT. For each imaging modality, a standard 17-segment cardi"},{"nctId":"NCT06554522","phase":"PHASE4","title":"Pragmatic Evaluation of Respiratory Distress Syndrome Treatment in Africa","status":"RECRUITING","sponsor":"Indiana University","startDate":"2025-01-01","conditions":"Respiratory Distress Syndrome in Premature Infant, RDS of Prematurity, Surfactant Deficiency Syndrome Neonatal","enrollment":1512,"completionDate":"2027-12-30","primaryEndpoint":"Hospital Survival"},{"nctId":"NCT06127667","phase":"NA","title":"Brain Vascular and Neural Function Linked to Balance Across the Adult Lifespan","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2024-10-15","conditions":"Neurotypical, Cognitively Normal","enrollment":102,"completionDate":"2028-07-01","primaryEndpoint":"cerebral blood flow velocity assessed using transcranial Doppler ultrasound"},{"nctId":"NCT07494201","phase":"NA","title":"MIMICC Study in Patients With Colorectal Cancer","status":"RECRUITING","sponsor":"Fondazione del Piemonte per l'Oncologia","startDate":"2025-09-15","conditions":"Colorectal Cancer, Colon Cancer, Rectal Cancers","enrollment":2500,"completionDate":"2028-06-30","primaryEndpoint":"Diagnostic accuracy of fecal microbiome and fecal microRNA molecular signatures"},{"nctId":"NCT07413198","phase":"NA","title":"BOOST: Blended Onsite and Offsite Structured Exercise Training and Coaching","status":"NOT_YET_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2026-05","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":14,"completionDate":"2027-03","primaryEndpoint":"Exercise self-efficacy scales Scores"},{"nctId":"NCT07498777","phase":"NA","title":"Individual Alpha Frequency-Based rTMS for Post-Stroke Motor Recovery: Efficacy and Neurophysiological Mechanisms","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2026-04-01","conditions":"Ischemic Stroke","enrollment":34,"completionDate":"2028-03-31","primaryEndpoint":"National Institutes of Health Stroke Scale(NIHSS)"},{"nctId":"NCT06778122","phase":"NA","title":"In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors","status":"RECRUITING","sponsor":"University College, London","startDate":"2026-01-23","conditions":"Cancer Survivors, Cardiotoxicity, Cardiovascular Toxicity Induced by Antitumoral Drugs","enrollment":10,"completionDate":"2026-07-31","primaryEndpoint":"C-reactive protein (CRP)"},{"nctId":"NCT01900132","phase":"NA","title":"Electrical Impedance Myography: Natural History Studies inNeuromuscular Disorders and Healthy Volunteers","status":"RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2013-06-20","conditions":"Neuromuscular Disease, Motor Neuron Disease, Inherited Neuromuscular Conditions","enrollment":275,"completionDate":"2026-06-01","primaryEndpoint":"Patients - EIM measures for a selection of muscles"},{"nctId":"NCT06192758","phase":"NA","title":"Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Scientific Corporation","startDate":"2024-04-15","conditions":"Prostate, Cancer","enrollment":36,"completionDate":"2032-10","primaryEndpoint":"Maximum tolerated radiation dose of TheraSphere PCa"},{"nctId":"NCT07497334","phase":"NA","title":"A Novel Multi-Modal Approach to Promote Functional Outcomes in Cognitively Frail Older Adults","status":"RECRUITING","sponsor":"The Hong Kong Polytechnic University","startDate":"2025-01-05","conditions":"Frailty at Older Adults, Mild Cognitive Impairment","enrollment":45,"completionDate":"2027-06-30","primaryEndpoint":"Montreal Cognitive Assessment"},{"nctId":"NCT07489885","phase":"PHASE2","title":"A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis","status":"NOT_YET_RECRUITING","sponsor":"InventisBio Co., Ltd","startDate":"2026-05","conditions":"Psoriasis","enrollment":75,"completionDate":"2027-12","primaryEndpoint":"Improvement in PASI-90"},{"nctId":"NCT07398898","phase":"NA","title":"Use of Augmented Reality Glasses and Noise-Cancelling Headphones to Reduce Dental Anxiety in Adult Patients","status":"RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2026-03-01","conditions":"Dental Anxiety, Music Therapy, Oral Surgical Procedures","enrollment":250,"completionDate":"2026-06-30","primaryEndpoint":"Change in Self-Reported Anxiety Level (STAI Score)"},{"nctId":"NCT07383506","phase":"PHASE1","title":"A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Cogent Biosciences, Inc.","startDate":"2026-02","conditions":"PIK3CA Mutations, Advanced Solid Tumors, Adult, Endometrial Cancer","enrollment":90,"completionDate":"2029-08","primaryEndpoint":"Incidence and grade of Adverse Events (AEs) and Serious Adverse Events (SAEs) [Phase 1a]"},{"nctId":"NCT07498634","phase":"PHASE3","title":"Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active AS","status":"COMPLETED","sponsor":"Zhejiang Kanova Biopharmaceutical Co., LTD","startDate":"2023-09-21","conditions":"Phase III","enrollment":323,"completionDate":"2025-11-14","primaryEndpoint":"Is ASAS 40 achieved at W16?"},{"nctId":"NCT04036331","phase":"NA","title":"Dyad Plus Effectiveness/Feasibility","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2021-07-30","conditions":"Weight Loss, Pediatric Obesity, Overweight Adolescents","enrollment":90,"completionDate":"2026-04","primaryEndpoint":"BMI z-score"},{"nctId":"NCT07487974","phase":"NA","title":"Active Oxygen and Negative Ion Sanitary Pads for Episiotomy Pain, Healing, and Postpartum Symptoms","status":"RECRUITING","sponsor":"KTO Karatay University","startDate":"2025-11-01","conditions":"Episiotomy, Episiotomy Wound, Postpartum Complication","enrollment":76,"completionDate":"2026-06-30","primaryEndpoint":"Episiotomy Pain Score"},{"nctId":"NCT03947827","phase":"PHASE3","title":"Minocycline as Adjunctive Treatment for Treatment Resistant Depression","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2020-02-01","conditions":"Treatment Resistant Depression","enrollment":76,"completionDate":"2025-01-07","primaryEndpoint":"Depressive symptoms"},{"nctId":"NCT07388524","phase":"PHASE3","title":"Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-09","conditions":"Lung Non-Small Cell Carcinoma","enrollment":336,"completionDate":"2029-09-30","primaryEndpoint":"Disease-free survival"},{"nctId":"NCT06886906","phase":"NA","title":"Exploring the Acute and Dynamic Relationships Between Movement and Pain in Older Adults With Musculoskeletal Pain","status":"RECRUITING","sponsor":"Indiana University","startDate":"2024-11-13","conditions":"Older People, Pain","enrollment":40,"completionDate":"2026-08-01","primaryEndpoint":"Mechanical Temporal Summation of Pain (TS)"},{"nctId":"NCT04928209","phase":"NA","title":"Teletherapy in Children Who Are Deaf and Hard of Hearing","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2021-07-15","conditions":"Hearing Loss, Speech and Language Development Delay Due to Hearing Loss","enrollment":210,"completionDate":"2025-12-17","primaryEndpoint":"PLS-5 Auditory Comprehension (AC) Standard Score - 18 month"},{"nctId":"NCT07340554","phase":"NA","title":"Neuroimaging of Adolescent Cannabis Use Treatment","status":"RECRUITING","sponsor":"Indiana University","startDate":"2026-04","conditions":"Cannabis Use, Cannabis Dependence, Cannabis Use Disorder","enrollment":80,"completionDate":"2030-07","primaryEndpoint":"Cannabis use frequency"},{"nctId":"NCT07141888","phase":"NA","title":"The Effects of a Probiotic Food Supplement in Hyperuricaemia","status":"RECRUITING","sponsor":"Örebro University, Sweden","startDate":"2025-12-16","conditions":"Hyperuricemia With or Without Gout","enrollment":99,"completionDate":"2027-12","primaryEndpoint":"Effect of a 6-week intake of a probiotic product on blood urate levels in hyperuricaemic individuals compared to placebo"},{"nctId":"NCT07495995","phase":"PHASE2","title":"Single-Center Phase II Double-Blind Trial of SAMe to Prevent Liver Cancer in MASLD-Related Cirrhosis","status":"NOT_YET_RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2026-04-15","conditions":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","enrollment":94,"completionDate":"2031-12-31","primaryEndpoint":"Change in Prognostic Liver Secretome signature (PLSec) score"},{"nctId":"NCT07439666","phase":"NA","title":"NEUROCUPLE™ as an Opioid Alternative Following Total Knee Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"Jacques E. Chelly","startDate":"2026-03-31","conditions":"Total Knee Arthroplasty Postoperative Pain, Opioid Reduction After TKA","enrollment":274,"completionDate":"2027-11","primaryEndpoint":"Opioid Consumption"}],"_emaApprovals":[{"date":"","name":"Active","holder":"","status":"Authorised","rawText":"Skip to main content\nAn official website of the European Union\nHow do you know?\n\nWe use cookies on this website. Essential cookies allow it to work properly. Non-essential cookies allow us to collect anonymous data to improve our services. You can opt out of non-essential cookies at any time.\n\nMore information: Cookies and Europa Analytics (user behaviour data)\n\nAccept all cookies\nAccept only essential cookies\nSearch\nSelect how you want to search using keywords\nMedicines\nHuman regulatory\nVeterinary regulatory\nCommittees\nNews & events\nPartners & networks\nAbout us\nHome\nPage or document not found","regulator":"EMA","indication":""}],"_faersSignals":[{"count":197,"reaction":"FATIGUE"},{"count":166,"reaction":"DIARRHOEA"},{"count":150,"reaction":"HEADACHE"},{"count":135,"reaction":"PAIN"},{"count":130,"reaction":"NAUSEA"},{"count":128,"reaction":"DYSPNOEA"},{"count":113,"reaction":"DIZZINESS"},{"count":111,"reaction":"PRODUCT DOSE OMISSION ISSUE"},{"count":101,"reaction":"DRUG INEFFECTIVE"},{"count":90,"reaction":"FALL"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_mhraApprovals":[{"name":"Active","holder":"","status":"Licensed","licence":"PL 12345/0001","rawText":"MHRA does not collect any data that would identify you directly. We would like to use Google Analytics to help us improve our services. You can allow this by clicking accept all cookies or find out more first by visiting our cookie policy page.\n\nAccept all cookies\nProducts\nEnter a product, active substance, or PL number:\n\nor find by active substance:\n\nA\nB\nC\nD\nE\nF\nG\nH\nI\nJ\nK\nL\nM\nN\nO\nP\nQ\nR\nS\nT\nU\nV\nW\nX\nY\nZ\n0\n1\n2\n3\n4\n5\n6\n7\n8\n9\n\nReport a side effect with a medicine or medical device\n\nMake a report\nShowing results for Active\n\n1 to 10 of 69412\n\nIf the product information you are seeking does not appea","regulator":"MHRA"}],"administration":{"icon":"","route":"Topical","frequency":"","formulation":"Nasal spray"},"_hyperScrapedAt":"2026-03-27T18:48:16.114695","crossReferences":{"unii":"G63QQF2NOX","splId":"48c1b93c-9c70-95aa-e063-6294a90a0cfa","chemblId":"CHEMBL4802227","pubchemSID":"381128316"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":1310986,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"firstApprovalDate":"","recentPublications":[{"date":"2026 Mar 27","pmid":"41891211","title":"Orbital-Selective Modulation of Spatial p(z)-s Hybridization for Enhanced Photocatalytic H(2) Evolution: Insights From NiSe@ReS(2+) (x) Cocatalyst.","authors":"Gao D","journal":"Angewandte Chemie (International ed. in English)"},{"date":"2026 Apr","pmid":"41891207","title":"Family Members' Experiences of Weaning From Mechanical Ventilation in Intensive Care: A Hermeneutic Phenomenological Study.","authors":"Tingsvik C","journal":"Nursing open"},{"date":"2026 Mar 27","pmid":"41891157","title":"Association Between Healthy Lifestyle Behaviors and Mental Health Symptoms in Children With Autism and ADHD: A Latent Profile Analysis.","authors":"Bourke M","journal":"Autism research : official journal of the International Society for Autism Research"},{"date":"2026 Mar 27","pmid":"41891141","title":"Divergent Thioamide Synthesis via Umpolung C-N Bond Formation from Nitroethane in Aqueous Medium.","authors":"Bhatt PR","journal":"The Journal of organic chemistry"},{"date":"2026","pmid":"41891070","title":"#TransTok: A digital ethnographic study using content analysis to investigate transgender and gender diverse 'for you page' content on TikTok that may affect mental health.","authors":"Paciente R","journal":"International journal of transgender health"}],"_hyperScrapedFields":["patents","pricing","trials","ema","mhra","who","safety-signals","recalls","dailymed","pubmed","drugbank","chembl","rxnorm","medicare","pharmgkb","sec","company-ir","wikipedia","drug-website","google"],"companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"","enrichmentLevel":3,"visitCount":8,"trialStats":{"total":19,"withResults":2},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}